Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study (INHX, PFE)

Inhibitex INHX, announced today that Pfizer Inc. PFE presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine (SA3Ag) at the 21^st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 27^th International Congress of Chemotherapy (ICC) in Milan, Italy (ECCMID/ICC). The vaccine candidate is comprised of S. aureus capsular polysaccharide serotypes 5 and 8 conjugated to CRM[197] and the recombinant surface-expressed MSCRAMM protein, clumping factor A. In the Phase 1 study, the vaccine elicited a positive immune response to each of the three components. Pfizer has worldwide exclusive rights to the Company's MSCRAMM protein platform for the development of taphylococcal vaccines.